Q-omics provides the consensus-scored H2AC13 profile across patient tissues and cancer cell-line models. H2AC13 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, H2AC13 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, H2AC13 RNA expression shows 21,242 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, HNSC, and LUAD as cancer lineages where H2AC13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2AC13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2AC13 survival associations across molecular data types. H2AC13 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2AC13 RNA expression–survival associations across cancer types. High H2AC13 expression shows unfavorable associations in KIRP, ACC, LGG and PAAD, but favorable associations in CESC and OV. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for H2AC13 RNA expression.
This table summarizes H2AC13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for H2AC13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2AC13 shows lower tumor expression in COAD and higher tumor expression in HNSC, KIRC, LUAD, LIHC and BRCA. The HNSC box plot shows higher H2AC13 RNA expression in tumor versus normal tissue (log2 FC = +1.668, t-test p < 0.001).
This table shows molecular features associated with H2AC13 in patient tissues and cancer cell lines. In patient samples, H2AC13 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, H2AC13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
